INDEPENDENT BIOTECH CONSULTANCY FOR ANTIBODY PROGRAMS
Practical support for antibody discovery and early development.
Concido Therapeutics helps biotech startups make sound decisions on targets, modalities, lead candidates and development plans, and keeps the program on track while they are carried out.
20+
years in antibody and VHH discovery and engineering
7+
patents as co-inventor
4
disease areas: oncology, autoimmunity, obesity and cardiovascular disease
Questions clients bring
Each one gets a clear recommendation with the reasoning behind it, not a list of options.
Which modality and antibody format fit this target?
Is our assay strategy strong enough to pick a lead on?
Which lead candidate do we advance, and which do we drop?
What does a realistic plan to the clinic look like, with clear Go/No-Go gates?
What does this dataset really tell us, and what do we tell investors?
Where we step in
One advisor from target biology to a milestone-driven development plan, so early decisions still hold up later.
Target and modality. Target biology, modality selection and antibody format choice.
Discovery. Antibody discovery strategy, assay strategy and oversight of the work at CROs.
Lead triage. Data review, lead candidate triage and the call on which molecules to advance.
Preclinical planning. Preclinical development plan with timelines, risk areas and milestones.
Go/No-Go decisions. Decision gates and clear recommendations for founders, investors and R&D teams.
Recent work
Client names and targets stay confidential. The kind of work does not have to.
Format. Triaged trispecific antibody formats and delivered one recommended design with its rationale.
CRO selection. Compared two competing CRO proposals for an IgG reformatting and screening campaign, scope against budget.
Optimization. Steered an affinity maturation campaign at a CRO and advised which clones to advance.
Manufacturing. Mapped and approached CDMOs for multiple antibody modalities.
Intelligence. Competitive and patent read on a clinical-stage antibody, down to how it is manufactured.
Three ways to engage
Program and project lead
Set days per month inside your team, aligning scientific priorities, team execution and investor needs.
For startups before their first senior biologics hire.
Scoped project
One question, one deliverable: a modality recommendation, a lead triage, a development plan.
For teams with a decision due this quarter.
Independent data review
A critical read of a dataset or program to strengthen decisions and identify risks early.
For founders, investors and R&D teams.
WHO YOU WORK WITH
Wouter Pos, PhD
Founder and independent biotech consultant, Concido Therapeutics, since 2024.
Formerly Director of Antibody Technologies at VectorY Therapeutics. Before that at AIMM Therapeutics, as co-inventor on the AML antigen patent family and co-author on the AT1412 (CD9) work. He is also co-inventor on patents for AAV-delivered antibody therapeutics.
Wouter also brings AI into biotech R&D. As Scientific Director at BioSemia he leads the science behind AI tools for preclinical imaging, which get more information out of the microscopy data labs already collect. He helps biotech teams put AI to practical use in their own data and workflows.
You work with Wouter directly. No junior team, no handover.
Thirty minutes, no obligation.
Tell us where your program stands. You will hear plainly whether Concido can help, under a CDA if needed.
Concido Therapeutics · Amsterdam, The Netherlands · KvK 99446308